マーケットレポート詳細
創傷ケア用バイオ医薬品の世界市場：製品別、創傷タイプ別2027年予測
Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027
- 出版元：MarketsandMarkets
出版元について - 発行年：2022年6月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文174ページになります。
- 商品コード：MAM2957
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
創傷ケア用バイオ医薬品の世界市場規模は2022年で18億ドル、2027年に24億ドル、市場の平均年成長率は5.4%で推移する見込みです。
レポートは創傷ケア用バイオ医薬品の世界市場について2027年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（製品別市場、創傷タイプ別市場、等）を中心に構成されています。また競合状況、主要企業情報（12社）、COVID-19の影響、市場シェア分析、競合状況などの分析も加味し、創傷ケア用バイオ医薬品市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆創傷ケア用バイオ医薬品の世界市場予測2017-2027年
・市場規模(US$)
◆製品別、市場-2027年
皮膚代用品
・ヒトドナー組織由来製品
・無細胞系動物由来製品
・生合成製品
外用剤
※(市場規模US$)
◆創傷タイプ別、市場-2027年
潰瘍
・糖尿病性足潰瘍
・静脈潰瘍
・褥瘡
・その他潰瘍
手術/外傷
火傷
※(市場規模US$)
◆エンドユーザー別、市場-2027年
・病院
・外来手術センター
・火傷治療センター/創傷クリニック
※(市場規模US$)
◆主要国地域別市場-2027年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
中東アフリカ
※地域別に全セグメントの細分化データ掲載
※国別に製品大分類別、創傷タイプ大分類別、エンドユーザー別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会)
・COVID-19の影響
・市場シェア分析
・競合状況
◆創傷ケア用バイオ医薬品の主要企業プロフィール動向
・SMITH & NEPHEW PLC
・ORGANOGENESIS INC.
・MIMEDX
・INTEGRA LIFESCIENCES
・STRYKER CORPORATION
・MÖLNLYCKE HEALTH CARE AB
・VERICEL CORPORATION
・ANIKA THERAPEUTICS, INC.
・BIOVENTUS LLC
・ABBVIE INC.
・KERECIS
・MARINE POLYMER TECHNOLOGIES, INC.
(その他企業)
・MERAKRIS THERAPEUTICS
・POLYMEDICS INNOVATIONS GMBH
・FIBROHEAL WOUNDCARE PVT. LTD.
・ANAMAY BIOTECH, INC.
・VIRCHOW BIOTECH PRIVATE LIMITED
・MEDLINE INDUSTRIES, LP
・TIDES MEDICAL
・VISCUS BIOLOGICS LLC
・STABILITY BIOLOGICS
・MTF BIOLOGICS
・SKYE BIOLOGICS HOLDINGS, LLC
・ALLOSOURCE
・SURGILOGIX
（全174頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED 28
・ FIGURE 1 WOUND CARE BIOLOGICS MARKET
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
・ FIGURE 2 WOUND CARE BIOLOGICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 KEY DATA FROM SECONDARY SOURCES
2.2.2 PRIMARY DATA
2.2.2.1 PRIMARY SOURCES
2.2.2.2 KEY DATA FROM PRIMARY SOURCES
2.2.2.3 KEY INDUSTRY INSIGHTS
・ FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
・ FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 APPROACH 3: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
2.3.1.3 GROWTH FORECAST
2.3.1.4 CAGR PROJECTIONS
・ FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH 38
・ FIGURE 6 WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
・ FIGURE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION)
・ FIGURE 9 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2022 VS. 2027 (USD MILLION)
・ FIGURE 10 WOUND CARE BIOLOGICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION)
・ FIGURE 11 WOUND CARE BIOLOGICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 WOUND CARE BIOLOGICS MARKET OVERVIEW
・ FIGURE 12 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET FOR WOUND CARE BIOLOGICS
4.2 WOUND CARE BIOLOGICS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
・ FIGURE 13 BIOLOGICAL SKIN SUBSTITUTES WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3 WOUND CARE BIOLOGICS MARKET SHARE, BY WOUND TYPE, 2022 VS. 2027
・ FIGURE 14 ULCERS SEGMENT DOMINATES MARKET
4.4 WOUND CARE BIOLOGICS MARKET SHARE, BY END USER, 2022 VS. 2027
・ FIGURE 15 HOSPITALS ARE LARGEST END USERS OF WOUND CARE BIOLOGICS
4.5 WOUND CARE BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・ FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN WOUND CARE BIOLOGICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 17 WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 GROWING PREVALENCE OF DISEASES & CONDITIONS AFFECTING WOUND HEALING CAPABILITIES
5.2.1.1.1 GROWING GERIATRIC POPULATION
5.2.1.1.2 INCREASING PREVALENCE OF DIABETES AND TARGET CONDITIONS
・ FIGURE 18 PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION,
2021 VS. 2045 (MILLION CASES)
・ TABLE 1 TOTAL HEALTH EXPENDITURE (USD) DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY
・ TABLE 2 LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS
5.2.1.1.3 INCREASING NUMBER OF SURGICAL PROCEDURES ACROSS THE GLOBE
5.2.1.1.4 INCREASING NUMBER OF TRAUMATIC WOUNDS
・ TABLE 3 PREVALENCE OF ROAD ACCIDENTS
5.2.1.2 INCREASING INCIDENCE OF BURN INJURIES
5.2.1.3 INNOVATIONS IN WOUND CARE BIOLOGICS
5.2.2 MARKET RESTRAINTS 52
5.2.2.1 HIGH COST OF WOUND CARE BIOLOGIC PRODUCTS
・ TABLE 4 AVERAGE COST OF TREATMENT FOR DIABETIC FOOT ULCERS (2018)
5.2.2.2 RISK OF SKIN SUBSTITUTE FAILURE
・ TABLE 5 COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS)
5.2.3 OPPORTUNITIES
5.2.3.1 GROWTH POTENTIAL OF EMERGING ECONOMIES
・ TABLE 6 STRATEGIC DEVELOPMENTS IN THE ASIA PACIFIC
5.2.3.2 3D SKIN PRINTING
5.3 IMPACT OF COVID-19 ON THE WOUND CARE BIOLOGICS MARKET
6 WOUND CARE BIOLOGICS MARKET, BY PRODUCT
6.1 INTRODUCTION
・ TABLE 7 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
6.2 BIOLOGICAL SKIN SUBSTITUTES
・ TABLE 9 KEY PRODUCTS IN THE BIOLOGICAL SKIN SUBSTITUTES MARKET
・ TABLE 10 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 11 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2021–2027 (USD MILLION)
・ TABLE 12 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2017–2020 (USD MILLION)
・ TABLE 13 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2021–2027 (USD MILLION)
6.2.1 HUMAN DONOR TISSUE-DERIVED PRODUCTS
6.2.1.1 HIGH EFFICACY OF HUMAN DONOR TISSUE-DERIVED PRODUCTS TO SUPPORT MARKET DEMAND
・ TABLE 14 KEY PRODUCTS IN THE HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET
・ TABLE 15 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,
2017–2020 (USD MILLION)
・ TABLE 16 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,
2021–2027 (USD MILLION)
6.2.2 ACELLULAR ANIMAL-DERIVED PRODUCTS
6.2.2.1 RECOGNITION OF THE IMPORTANCE OF ECM IN WOUND TREATMENT HAS LED TO THE DEVELOPMENT OF ACELLULAR WOUND CARE BIOLOGICS
・ TABLE 17 KEY PRODUCTS IN THE ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET
・ TABLE 18 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,
2017–2020 (USD MILLION)
・ TABLE 19 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,
2021–2027 (USD MILLION)
6.2.3 BIOSYNTHETIC PRODUCTS
6.2.3.1 INCREASED BIOBURDEN OF INFECTED WOUNDS TO STIMULATE MARKET GROWTH 64
・ TABLE 20 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 21 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3 TOPICAL AGENTS
6.3.1 INCREASE IN THE NUMBER OF CHRONIC ULCERS OVER THE LAST FEW YEARS TO PROPEL MARKET GROWTH
・ TABLE 22 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 23 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2021–2027 (USD MILLION)
7 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE
7.1 INTRODUCTION
・ TABLE 24 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 25 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
7.1.1 PRIMARY NOTES
7.1.1.1 KEY INDUSTRY INSIGHTS
7.2 ULCERS
・ TABLE 26 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2017–2020 (USD MILLION)
・ TABLE 27 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2021–2027 (USD MILLION)
・ TABLE 28 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2017–2020 (USD MILLION)
・ TABLE 29 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2021–2027 (USD MILLION)
7.2.1 DIABETIC FOOT ULCERS
7.2.1.1 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET GROWTH
・ TABLE 30 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 31 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2021–2027 (USD MILLION)
7.2.2 VENOUS ULCERS
7.2.2.1 RISING PREVALENCE OF OBESITY TO DRIVE MARKET GROWTH
・ TABLE 32 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 33 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2021–2027 (USD MILLION)
7.2.3 PRESSURE ULCERS 73
7.2.3.1 GROWING GERIATRIC POPULATION TO DRIVE MARKET GROWTH
・ TABLE 34 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 35 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2021–2027 (USD MILLION)
7.2.4 OTHER ULCERS
・ TABLE 36 COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS
・ TABLE 37 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,
2017–2020 (USD MILLION)
・ TABLE 38 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,
2021–2027 (USD MILLION)
7.3 SURGICAL & TRAUMATIC WOUNDS
7.3.1 RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
・ TABLE 39 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 40 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2021–2027 (USD MILLION)
7.4 BURNS
7.4.1 HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH
・ TABLE 41 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2017–2020 (USD MILLION)
・ TABLE 42 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2021–2027 (USD MILLION)
8 WOUND CARE BIOLOGICS MARKET, BY END USER
8.1 INTRODUCTION
・ TABLE 43 WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 44 WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
8.2 HOSPITALS
8.2.1 INCREASING NUMBER OF HOSPITALS & HIGH PATIENT INFLOW IN THIS CARE SETTING TO SUPPORT MARKET GROWTH
・ TABLE 45 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,
2017–2020 (USD MILLION)
・ TABLE 46 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,
2021–2027 (USD MILLION)
8.3 AMBULATORY SURGERY CENTERS
8.3.1 GROWING NUMBER OF SURGICAL PROCEDURES PERFORMED IN ASCS WILL ENSURE MARKET GROWTH IN THIS SEGMENT
・ TABLE 47 NUMBER OF BURN PATIENTS PER 1,000 ASC ADMISSIONS
・ TABLE 48 PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGERY CENTERS IN THE US
・ TABLE 49 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 50 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2027 (USD MILLION)
8.4 BURN CARE CENTERS & WOUND CLINICS
8.4.1 RISING GERIATRIC POPULATION AND THE SUBSEQUENT INCREASE IN THE DEMAND FOR ASSISTED LIVING FACILITIES TO SUPPORT MARKET GROWTH
・ TABLE 51 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 52 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2021–2027 (USD MILLION)
9 WOUND CARE BIOLOGICS MARKET, BY REGION
9.1 INTRODUCTION
・ TABLE 53 WOUND CARE BIOLOGICS MARKET, BY REGION, 2017–2020 (USD MILLION)
・ TABLE 54 WOUND CARE BIOLOGICS MARKET, BY REGION, 2021–2027 (USD MILLION)
9.2 NORTH AMERICA
・ FIGURE 19 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT
・ TABLE 55 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)
・ TABLE 56 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)
・ TABLE 57 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 58 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 59 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
・ TABLE 60 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
・ TABLE 61 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 62 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.2.1 US
9.2.1.1 INCREASING PREVALENCE OF DIABETES AND NON-HEALING FOOT ULCERS TO SUPPORT THE UPTAKE OF WOUND BIOLOGICS PRODUCTS
・ TABLE 63 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 64 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 65 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 66 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 67 US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 68 US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 RISING GERIATRIC PATIENT POOL TO DRIVE MARKET GROWTH FOR WOUND BIOLOGICS IN CANADA
・ TABLE 69 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
・ TABLE 70 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 71 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 72 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 73 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 74 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 75 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3 EUROPE
・ TABLE 76 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)
・ TABLE 77 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)
・ TABLE 78 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 79 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 80 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 81 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 82 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 83 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.1 UK
9.3.1.1 INCREASING INCIDENCE OF VENOUS ULCERS TO DRIVE THE MARKET GROWTH
・ TABLE 84 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 85 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 86 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 87 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 88 UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 89 UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 THE LARGE DIABETIC POPULATION IN GERMANY SUPPORTS THE UPTAKE OF WOUND BIOLOGICS IN GERMANY
・ TABLE 90 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 91 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 92 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 93 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 94 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 95 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 RISING GOVERNMENT SUPPORT TO DRIVE THE DEMAND FOR WOUND CARE BIOLOGICS PRODUCTS IN FRANCE
・ TABLE 96 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 97 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 98 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 99 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 100 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 101 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.3.4 REST OF EUROPE
・ TABLE 102 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 103 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 104 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 105 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 106 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 107 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4 ASIA PACIFIC
・ FIGURE 20 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET SNAPSHOT
・ TABLE 108 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION)
・ TABLE 109 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION)
・ TABLE 110 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 111 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 112 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 113 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 114 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 115 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 INCREASING INCIDENCE OF DFUS TO PROPEL THE MARKET GROWTH
・ TABLE 116 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 117 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 118 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 119 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 120 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 121 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 GROWING GERIATRIC POPULATION TO DRIVE THE ADOPTION OF WOUND CARE PRODUCTS
・ TABLE 122 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 123 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 124 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 125 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 126 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 127 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 GROWING MEDICAL TOURISM IN THE COUNTRY TO SUPPORT THE MARKET GROWTH FOR WOUND BIOLOGICS
・ TABLE 128 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 129 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 130 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 131 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 132 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 133 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
・ TABLE 134 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 135 ROAPAC WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 136 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION)
・ TABLE 137 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION)
・ TABLE 138 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 139 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE MARKET GROWTH
・ TABLE 140 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION)
・ TABLE 141 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION)
・ TABLE 142 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
・ TABLE 143 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
・ TABLE 144 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION)
・ TABLE 145 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 SIGNIFICANT GROWTH IN HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET GROWTH FOR WOUND BIOLOGICS
・ TABLE 146 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
・ TABLE 147 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
・ TABLE 148 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION)
・ TABLE 149 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION)
・ TABLE 150 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION)
・ TABLE 151 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE WOUND CARE BIOLOGICS MARKET
・ TABLE 152 OVERVIEW OF STRATEGIES DEPLOYED BY KEY WOUND CARE BIOLOGICS MANUFACTURING COMPANIES
10.3 MARKET SHARE ANALYSIS
10.3.1 WOUND CARE BIOLOGICS MARKET
・ FIGURE 21 WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER (2021)
・ TABLE 153 WOUND CARE BIOLOGICS MARKET: DEGREE OF COMPETITION
10.4 COMPANY EVALUATION QUADRANT
10.4.1 LIST OF EVALUATED VENDORS
10.4.2 STARS
10.4.3 EMERGING LEADERS
10.4.4 PERVASIVE PLAYERS
10.4.5 PARTICIPANTS
・ FIGURE 22 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS 136
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES 136
・ FIGURE 23 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
10.6 COMPETITIVE SCENARIO 137
10.6.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
・ TABLE 154 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
10.6.2 DEALS
・ TABLE 155 KEY DEALS
10.6.3 OTHER DEVELOPMENTS
・ TABLE 156 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESS AND COMPETITIVE THREATS)*
11.1.1 SMITH & NEPHEW PLC
・ TABLE 157 SMITH & NEPHEW PLC: BUSINESS OVERVIEW
・ FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021)
11.1.2 ORGANOGENESIS INC.
・ TABLE 158 ORGANOGENESIS INC.: BUSINESS OVERVIEW
・ FIGURE 25 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2021)
11.1.3 MIMEDX
・ TABLE 159 MIMEDX: BUSINESS OVERVIEW
・ FIGURE 26 MIMEDX: COMPANY SNAPSHOT (2021)
11.1.4 INTEGRA LIFESCIENCES
・ TABLE 160 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
・ FIGURE 27 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021)
11.1.5 STRYKER CORPORATION
・ TABLE 161 STRYKER CORPORATION: BUSINESS OVERVIEW
・ FIGURE 28 STRYKER CORPORATION: COMPANY SNAPSHOT (2021)
11.1.6 MÖLNLYCKE HEALTH CARE AB
・ TABLE 162 MÖLNLYCKE HEALTH CARE AB: BUSINESS OVERVIEW
・ FIGURE 29 MÖLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2021)
11.1.7 VERICEL CORPORATION
・ TABLE 163 VERICEL CORPORATION: BUSINESS OVERVIEW
・ FIGURE 30 VERICEL CORPORATION: COMPANY SNAPSHOT (2021)
11.1.8 ANIKA THERAPEUTICS, INC.
・ TABLE 164 ANIKA THERAPEUTICS, INC.: BUSINESS OVERVIEW
・ FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2021)
11.1.9 BIOVENTUS LLC
・ TABLE 165 BIOVENTUS LLC: BUSINESS OVERVIEW
・ FIGURE 32 BIOVENTUS LLC: COMPANY SNAPSHOT (2021)
11.1.10 ABBVIE INC.
・ TABLE 166 ABBVIE INC.: BUSINESS OVERVIEW
・ FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2021)
11.1.11 KERECIS
・ TABLE 167 KERECIS: BUSINESS OVERVIEW 165
11.1.12 MARINE POLYMER TECHNOLOGIES, INC.
・ TABLE 168 MARINE POLYMER TECHNOLOGIES, INC.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 MERAKRIS THERAPEUTICS
・ TABLE 169 MERAKRIS THERAPEUTICS: COMPANY OVERVIEW
11.2.2 POLYMEDICS INNOVATIONS GMBH
・ TABLE 170 POLYMEDICS INNOVATIONS GMBH: COMPANY OVERVIEW
11.2.3 FIBROHEAL WOUNDCARE PVT. LTD.
・ TABLE 171 FIBROHEAL WOUNDCARE PVT. LTD.: COMPANY OVERVIEW
11.2.4 ANAMAY BIOTECH, INC.
・ TABLE 172 ANAMAY BIOTECH, INC.: COMPANY OVERVIEW
11.2.5 VIRCHOW BIOTECH PRIVATE LIMITED
・ TABLE 173 VIRCHOW BIOTECH PRIVATE LIMITED: COMPANY OVERVIEW
11.2.6 MEDLINE INDUSTRIES, LP
・ TABLE 174 MEDLINE INDUSTRIES, LP: COMPANY OVERVIEW
11.2.7 TIDES MEDICAL
・ TABLE 175 TIDES MEDICAL: COMPANY OVERVIEW
11.2.8 VISCUS BIOLOGICS LLC
・ TABLE 176 VISCUS BIOLOGICS LLC: COMPANY OVERVIEW
11.2.9 STABILITY BIOLOGICS
・ TABLE 177 STABILITY BIOLOGICS: COMPANY OVERVIEW
11.2.10 MTF BIOLOGICS
・ TABLE 178 MTF BIOLOGICS: COMPANY OVERVIEW
11.2.11 SKYE BIOLOGICS HOLDINGS, LLC
・ TABLE 179 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW
11.2.12 ALLOSOURCE
・ TABLE 180 ALLOSOURCE: COMPANY OVERVIEW 172
11.2.13 SURGILOGIX
・ TABLE 181 SURGILOGIX: COMPANY OVERVIEW 173
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW, KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESS AND COMPETITIVE THREATS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
12 APPENDIX